Homepage
Author:
Vivos Therapeutics, Inc
Posted Date:
June 5, 2026
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Therapeutics, Inc
June 5, 2026
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
Vivos Therapeutics, Inc
April 7, 2026
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved ‘In-Network’ Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Vivos Therapeutics, Inc
March 26, 2026
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
Vivos Therapeutics, Inc
March 17, 2026
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Vivos Therapeutics, Inc
February 7, 2026
